FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1987262495> ?p ?o ?g. }

• W1987262495 endingPage "1701" @default.
• W1987262495 startingPage "1691" @default.
• W1987262495 abstract "Equivalence trials aim to show that two treatments have equivalent therapeutic effects. The approach is to define, in advance, a range of equivalence −d to +d for the treatment difference such that any value in the range is clinically unimportant. If the confidence interval for the difference, calculated after the trial, lies entirely within the interval, then equivalence is claimed. Glaxo Wellcome has carried out a series of trials using this methodology to assess new formulations of inhaled beta-agonists and inhaled steroids in asthma. Eleven of these trials are used to review some practical issues in equivalence trials. For the series of asthma trials, a range for peak expiratory flow rate (PEF) from −15 to +15l/min was chosen to be the range of equivalence. This fitted well with physicians' opinions and with previously demonstrated differences between active and placebo. The choice of the size of the confidence interval should depend on the medical severity of the clinical endpoints under consideration and the level of risk acceptable in assuming equivalence if a difference of potential importance exists. From this point of view, a recommendation in the CPMP Note for Guidance on Biostatistics that 95 per cent confidence intervals should be used is inappropriate. Intent-to-treat (ITT) and per-protocol (PP) analyses were compared for the eleven asthma trials. Confidence intervals were always wider for the PP analysis and this was entirely due to the smaller number of subjects included in the PP analysis. There was no evidence that the ITT analyses were more conservative in their estimates of treatment difference. The need to demonstrate equivalence in both an ITT and a PP analysis in a regulatory trial increases the regulatory burden on drug developers. The relative importance of the two analyses will depend on the definitions used in particular therapeutic areas. Demonstrating equivalence in one population with strong support from the other would be preferred from the Industry viewpoint. In trials with regulatory importance, prior agreement with regulators on the role of ITT and PP populations should be sought. Trial designs will need to take account of the estimated size of the PP population if adequate power is needed for both analyses. Careful design in the series of asthma trials, particularly identifying a population of patients with potential to improve, resulted in notable increases in lung function during the course of the trials for both treatments. This provided reassurance that equivalence was not due to a lack of efficacy for both treatments. In one trial equivalence was demonstrated overall but a treatment by country interaction was noted. However, this interaction could not be attributed to differences in patient characteristics or baseline data between the countries. Study conduct was also similar in the different countries. The conclusion was that the interaction was spurious and that the trial provided good evidence of equivalence. © 1998 John Wiley & Sons, Ltd." @default.
• W1987262495 created "2016-06-24" @default.
• W1987262495 creator A5039361617 @default.
• W1987262495 creator A5074770202 @default.
• W1987262495 date "1998-08-15" @default.
• W1987262495 modified "2023-10-11" @default.
• W1987262495 title "Practical issues in equivalence trials" @default.
• W1987262495 doi "https://doi.org/10.1002/(sici)1097-0258(19980815/30)17:15/16<1691::aid-sim971>3.0.co;2-j" @default.
• W1987262495 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9749440" @default.
• W1987262495 hasPublicationYear "1998" @default.
• W1987262495 type Work @default.
• W1987262495 sameAs 1987262495 @default.
• W1987262495 citedByCount "131" @default.
• W1987262495 countsByYear W19872624952012 @default.
• W1987262495 countsByYear W19872624952013 @default.
• W1987262495 countsByYear W19872624952014 @default.
• W1987262495 countsByYear W19872624952015 @default.
• W1987262495 countsByYear W19872624952016 @default.
• W1987262495 countsByYear W19872624952017 @default.
• W1987262495 countsByYear W19872624952018 @default.
• W1987262495 countsByYear W19872624952020 @default.
• W1987262495 countsByYear W19872624952021 @default.
• W1987262495 countsByYear W19872624952023 @default.
• W1987262495 crossrefType "journal-article" @default.
• W1987262495 hasAuthorship W1987262495A5039361617 @default.
• W1987262495 hasAuthorship W1987262495A5074770202 @default.
• W1987262495 hasConcept C105795698 @default.
• W1987262495 hasConcept C107130276 @default.
• W1987262495 hasConcept C118615104 @default.
• W1987262495 hasConcept C126322002 @default.
• W1987262495 hasConcept C140556311 @default.
• W1987262495 hasConcept C142724271 @default.
• W1987262495 hasConcept C204787440 @default.
• W1987262495 hasConcept C27081682 @default.
• W1987262495 hasConcept C2776042228 @default.
• W1987262495 hasConcept C2780069185 @default.
• W1987262495 hasConcept C33923547 @default.
• W1987262495 hasConcept C44249647 @default.
• W1987262495 hasConcept C535046627 @default.
• W1987262495 hasConcept C71924100 @default.
• W1987262495 hasConceptScore W1987262495C105795698 @default.
• W1987262495 hasConceptScore W1987262495C107130276 @default.
• W1987262495 hasConceptScore W1987262495C118615104 @default.
• W1987262495 hasConceptScore W1987262495C126322002 @default.
• W1987262495 hasConceptScore W1987262495C140556311 @default.
• W1987262495 hasConceptScore W1987262495C142724271 @default.
• W1987262495 hasConceptScore W1987262495C204787440 @default.
• W1987262495 hasConceptScore W1987262495C27081682 @default.
• W1987262495 hasConceptScore W1987262495C2776042228 @default.
• W1987262495 hasConceptScore W1987262495C2780069185 @default.
• W1987262495 hasConceptScore W1987262495C33923547 @default.
• W1987262495 hasConceptScore W1987262495C44249647 @default.
• W1987262495 hasConceptScore W1987262495C535046627 @default.
• W1987262495 hasConceptScore W1987262495C71924100 @default.
• W1987262495 hasIssue "15-16" @default.
• W1987262495 hasLocation W19872624951 @default.
• W1987262495 hasLocation W19872624952 @default.
• W1987262495 hasOpenAccess W1987262495 @default.
• W1987262495 hasPrimaryLocation W19872624951 @default.
• W1987262495 hasRelatedWork W1986131348 @default.
• W1987262495 hasRelatedWork W2013851350 @default.
• W1987262495 hasRelatedWork W2018206907 @default.
• W1987262495 hasRelatedWork W2073176560 @default.
• W1987262495 hasRelatedWork W2109586110 @default.
• W1987262495 hasRelatedWork W2331364533 @default.
• W1987262495 hasRelatedWork W2407924119 @default.
• W1987262495 hasRelatedWork W4249409261 @default.
• W1987262495 hasRelatedWork W4322724676 @default.
• W1987262495 hasRelatedWork W4376849537 @default.
• W1987262495 hasVolume "17" @default.
• W1987262495 isParatext "false" @default.
• W1987262495 isRetracted "false" @default.
• W1987262495 magId "1987262495" @default.
• W1987262495 workType "article" @default.